The Ruby trial leads to an FDA approval for dostarlimab + chemo in advanced/recurrent endometrial cancer, but only dMMR/MSI-H patients.

Quizartinib's label and REMS program provide some clear, but concerning, warnings about its toxicity.

The Ruby trial leads to an FDA approval for dostarlimab + chemo in advanced/recurrent endometrial cancer, but only dMMR/MSI-H patients. Quizartinib's label and REMS program provide some clear, but concerning, warnings about its toxicity.

Ruby Trial & Quizartinib Toxicity

OncoPharm is a podcast dedicated to all things oncology pharmacy.  Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer.  Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

Science

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

Share Ruby Trial & Quizartinib Toxicity

Sign up to save your podcasts

Ruby Trial & Quizartinib Toxicity

Ruby Trial & Quizartinib Toxicity

More shows like OncoPharm

Planet Money

NEJM This Week

JAMA Clinical Reviews

White Coat Investor Podcast

The Curbsiders Internal Medicine Podcast

Core IM | Internal Medicine Podcast

The ONS Podcast

ASCO Guidelines

Harrison's PodClass: Internal Medicine Cases and Board Prep

Home Cooking

The Curious Clinicians

Ninja Nerd

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions

WolverHeme Happy Hour